Literature DB >> 24667109

Regulatory T cells, maternal-foetal immune tolerance and recurrent miscarriage: new therapeutic challenging opportunities.

Jaume Alijotas-Reig1, Taisiia Melnychuk2, Josep Maria Gris3.   

Abstract

Because maternal alloreactive lymphocytes are not depleted during pregnancy, local and/or systemic mechanisms have to play a key role in altering the maternal immune response. Peripheral T regulatory cells (pTregs) at the maternal-foetal interface are necessary in situ to prevent early abortion, but only those pTregs that have been previously exposed to paternal alloantigens. It has been showed that pregnancy selectively stimulates the accumulation of maternal Foxp3(+)CD4(+)CD25(+) (Foxp3Tregs) cells with foetal specificity. Interestingly, after delivery, foetal-specific pTregs persist at elevated levels, maintain tolerance to pre-existing foetal antigen, and rapidly re-accumulate during subsequent pregnancy. pTreg up-regulation could be hypothesized as a possible future therapeutic strategy in humans.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Abortos recurrentes; Citocinas; Cytokines; Células NK/KIR; Fracaso implantatorio; Implantation failure; Linfocitos T reguladores; Maternal–foetal tolerance; Miscarriages; NK cells/KIR; Regulatory-T lymphocytes; Tolerancia maternofetal; Tratamiento; Treatment

Mesh:

Substances:

Year:  2014        PMID: 24667109     DOI: 10.1016/j.medcli.2014.01.033

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

Review 1.  The integrative roles of chemokines at the maternal-fetal interface in early pregnancy.

Authors:  Mei-Rong Du; Song-Cun Wang; Da-Jin Li
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

2.  Correlation between unexplained recurrent spontaneous abortion with CD4+CD25+ regulatory T-cell and killer cell immunoglobulin-like receptor levels.

Authors:  Xiaozhen Quan; Xuezhou Yang
Journal:  Exp Ther Med       Date:  2017-06-21       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.